Companies › Elpiscience (Suzhou) Biopharma
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ES014 | – | Phase 2 | Desmoid Tumor; Solid Tumor | Feb 2027 |
| ES102 | – | Phase 2 | Non-Small Cell Lung Cancer | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05717348 | ES014 | Phase 1 | Solid Tumor | Oncology | Feb 2027 |
| NCT06623136 | ES102 | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT07541430 | ES014 | Phase 2 | Desmoid Tumor | Oncology | Jan 2028 |
No annotated target.
–
EpicentRx Ryvu Therapeutics Criterium Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Inhibrx Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.